Skip to content
10-K

Annual Report

Compass Therapeutics, Inc. CMPX

0001171843-26-001337

← back to feed
Filed
Mar 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 27, 2026 180.09M sh
Capex FY 2025 · Dec 31, 2025 $25K
Capex FY 2025 · Dec 31, 2024 $44K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$49.14M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$44.86M
Cash And Equivalents FY 2025 · Dec 31, 2025 $30.64M
Cash And Equivalents FY 2025 · Dec 31, 2024 $43.48M
Stockholders Equity FY 2025 · Dec 31, 2025 $196.79M
Stockholders Equity FY 2025 · Dec 31, 2024 $125.23M
Stockholders Equity FY 2025 · Dec 31, 2023 $148.54M
Current Liabilities FY 2025 · Dec 31, 2025 $13.97M
Current Liabilities FY 2025 · Dec 31, 2024 $8.87M
Total Liabilities FY 2025 · Dec 31, 2025 $22.8M
Total Liabilities FY 2025 · Dec 31, 2024 $15.17M
Current Assets FY 2025 · Dec 31, 2025 $209.82M
Current Assets FY 2025 · Dec 31, 2024 $132.75M
Total Assets FY 2025 · Dec 31, 2025 $219.59M
Total Assets FY 2025 · Dec 31, 2024 $140.4M
Eps Basic FY 2025 · Dec 31, 2025 −$0.42
Eps Basic FY 2025 · Dec 31, 2024 −$0.36
Sga Expense FY 2025 · Dec 31, 2025 $16.87M
Sga Expense FY 2025 · Dec 31, 2024 $15.13M
Rd Expense FY 2025 · Dec 31, 2025 $55.97M
Rd Expense FY 2025 · Dec 31, 2024 $42.34M
Net Income FY 2025 · Dec 31, 2025 −$66.49M
Net Income FY 2025 · Dec 31, 2024 −$49.38M
Operating Income FY 2025 · Dec 31, 2025 −$72.84M
Operating Income FY 2025 · Dec 31, 2024 −$56.63M
Revenue FY 2025 · Dec 31, 2025 $0
Revenue FY 2025 · Dec 31, 2024 $850K
Shares Diluted FY 2025 · Dec 31, 2024 137.4M sh